Targeting TGF-β in prostate cancer: Therapeutic possibilities during tumor progression

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 227-234

  Jones, Elisabeth ^a   Pu, Hong ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis signaling; Prostate cancer; Smad targeting; TGF

Indexed keywords

2 G7; ANTINEOPLASTIC AGENT; AP 11014; AP 12009; BIOLOGICAL MARKER; CYTOKINE; DOXAZOSIN; GC 1008; LY 215799; LY 364947; LY 550410; LY 580276; TERAZOSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR PROMOTER; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG TARGETING; HUMAN; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; MALE; METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 64349120177     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802705696     Document Type: Review

References (64)

1. Kyprianou N. TGF-β signaling dictates therapeutic targeting in prostate cancer. Therapy 2008 ; 5 (1): 7-11
2. McEntee MF, Ziegler C, Reel D, et al. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. Am J Pathol 2008 ; 173 (1): 256-268 (Pubitemid 351947970)
3. Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 2008 ; 103 : 691-708 (Pubitemid 351240607)
4. Bruckheimer E, Kyprianou N. Apoptosis in prostate carcinogenesis: a growth regulator and a therapeutic target. Cell Tissue Res 2000 ; 301 : 153-162 (Pubitemid 30459862)
5. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004 ; 64 : 9209-9216 (Pubitemid 39665537)
6. Park J, Lee MG, Cho K, et al. Transforming growth factor-β 1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene 2003 ; 22 : 4314-4332 (Pubitemid 36897963)
7. Beck C, Schreiber H, Rowley DA. Role of TGF-β in immune-evasion of cancer. Microsc Res Tech 2001 ; 52 : 387-395 (Pubitemid 32167826)
8. Lu S, Lee J, Revelo M, et al. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 2007 ; 13 (19): 5692-5702 (Pubitemid 47583893)
9. Seoane J. The TGFβ pathway as a therapeutic target in cancer. Clin Transl Oncol 2008 ; 10 : 14-19
10. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001 ; 29 (2): 117-129 (Pubitemid 32952643)
11. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003 ; 425 (6958): 577-584 (Pubitemid 37280136)
12. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005 ; 118 (Pt16): 3573-3584
13. Vardouli L, Moustakas A, Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. Biol Chem 2005 ; 280 (12): 11448-11457 (Pubitemid 40418454)
14. Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989 ; 3 : 1515-1522 (Pubitemid 19260400)
15. Biswas S, Criswell TL, Wang SE, Arteaga CL. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007 ; 117 : 1305-1313 (Pubitemid 46718418)
16. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008 ; 15 (4): 841-849
17. Singh R, Bhasin S, Braga M, et al. Regulation of Myogenic Differentiation by Androgens: Cross-Talk between Androgen Receptor/{beta}-Catenin and Follistatin/TGF-{beta} Signaling Pathways. Endocrinology 2008 ; In press
18. van der Poel HG. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer. Eur Urol 2008 ; 48 (6): 1051-1058
19. Song K, Wang H, Krebs TL, et al. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res 2008 ; 68 (19): 8173-8182
20. Qi W, Gao S, Wang Z. Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem J 2008 ; 416 (3): 453-462
21. Wikstrom P, Damber JE, Bergh A. Role of Transforming Growth Factor-β 1 in Prostate Cancer. Microsc Res Tech 2001 ; 52 : 411-419 (Pubitemid 32167829)
22. Pinkas J, Teicher B. TGF-β in cancer and as a therapeutic. Biochem Pharmacol 2006 ; 72 : 523-529 (Pubitemid 44163293)
23. Siegel P, Massague J. Cytostatic and Apoptotic Actions of the TGF-β in Homeostasis and Cancer. Nat Rev Cancer 2003 ; 3 : 807-820 (Pubitemid 37376979)
24. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-β 1 on proliferation and death of rat prostatic cells. Endocrinology 1988 ; 127 : 2963-2968
25. Zhu B, Fukada K, Zhu H, Kyprianou N. Prohibitin and cofilin are intracellular effectors of transforming growth factor β signaling in human prostate cancer cells. Cancer Res 2006 ; 66 : 8640-8647 (Pubitemid 44449179)
26. Landström M, Heldin NE, Bu S, et al. Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells. Curr Biol 2000 ; 10 (9): 535-538 (Pubitemid 30308312)
27. Edlund S, Bu S, Schuster N, et al. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 2003 ; 14 (2): 529-544 (Pubitemid 36237014)
28. Edlund S, Lee SY, Grimsby S, et al. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005 ; 25 (4): 1475-1488 (Pubitemid 40204923)
29. Zhang S, Ekman M, Thakur N, et al. TGFbeta1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. Cell Cycle 2006 ; 5 (23): 2787-2795 (Pubitemid 44901741)
30. Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008 ; 10 (10): 1199-1207
31. Yamashita M, Fatyol K, Jin C, et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008 ; 31 (6): 918-924
32. Bachman K, Park BH. Duel nature of TGF-β signaling: tumor suppressor vs tumor promoter. Curr Opin Oncol 2005 ; 17 : 49-54 (Pubitemid 40179912)
33. Jakowlew S. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev 2006 ; 25 : 435 -57 34. Biswas S, Criswell T, Wang SE, Arteaga CL. Inhibition of Transforming Growth Factor-β Signaling in Human Cancer: Targeting a Tumor Supressor Network as a Therapeutic Strategy. Clin Cancer Res 2006 ; 12 (14): 4142-4146 (Pubitemid 44922360)
34. Wilkstrom P. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998 ; 37 : 19-29 (Pubitemid 28385181)
35. Reynolds AR, Kyprianou N. Growth factor signaling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2006 ; 147 : S144 -52 (Pubitemid 43237580)
36. Akhurst R, Derynck R. TGF-β signaling in cancer - a double-edged sword. Trends Cell Biol 2001 ; 11 (11): S44 -51 (Pubitemid 33001443)
37. Barcellos-Hoff MH, Medina D. New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res 2004 ; 7 : 33-36
38. Barrett JM, Rovedo MA, Tajuddin AM, et al. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGF-β and its receptor, TGF-β RII. Prostate 2006 ; 66 : 632-650
39. Derynck R, Akhurst R. Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nat Cell Biol 2007 ; 9 (9): 1000-1004 (Pubitemid 47338137)
40. Ao M, Williams K, Bhowmick MA, Hayward SW. Transforming growth factor-β promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 2006 ; 66 (16): 8007-8016 (Pubitemid 44299165)
41. Yue J, Mulder K. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-β. Methods Mol Biol 2000 ; 142 : 125-131
42. Buijs JT, Henriquez NV, van Overveld PG, et al. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 2007 ; 24 (8): 609-617 (Pubitemid 50003597)
43. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004 ; 303 (5659): 848-851 (Pubitemid 38174665)
44. Tuxhorn JA, McAlhany SJ, Yang F, et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002 ; 62 (21): 6021-6025 (Pubitemid 35244446)
45. Moutsopoulos NM, Wen J, Wahl SM. TGF-β and tumors - an ill-fated alliance. Curr Opin Oncol 2008 ; 20 : 234-240
46. Thomas A, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005 ; 8 : 369-380 (Pubitemid 41579832)
47. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001 ; 7 : 1118-1122 (Pubitemid 33010019)
48. Iyer S, Wang ZG, Akhtari M, et al. Targeting TGF-β Signaling for Cancer Therapy. Cancer Biol Ther 2005 ; 4 (3): 261-266
49. Podar K, Raje N, Anderson KC. Inhibition of the TGF-β Signaling Pathway in Tumor Cells. Recent Results Cancer Res 2007 ; 172 : 77-97
50. Schlingensiepen KH, Bischof A, Egger T, et al. The TGFbeta1 antisense oligonucleotide AP 11014 for treatment of nonsmall cell lung colorectal and prostate cancers: Preclinical studies. J Clin Oncol 2004 ; 22 (14S): 3132
51. Arteaga CL, Hurd SD, Winner AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993 ; 92 : 2569-2576 (Pubitemid 24006519)
52. Kaminska B, Wesolowska A, Danilkiewicz M. TGF beta signaling and its role in tumour pathogenesis. Acta Biochimica Polonica 2005 ; 52 (2): 329-337 (Pubitemid 41133768)
53. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2003 ; 109 : 1607-1615 (Pubitemid 34663523)
54. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002 ; 109 : 1551-1559 (Pubitemid 34663517)
55. Bandyopadhyay A, Zhu Y, Cibull ML, et al. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 1999 ; 59 (19): 5041-5046 (Pubitemid 29472913)
56. Bandyopadhyay A, Wang L, Lopez-Casillas F, et al. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 2005 ; 63 (1): 81-90 (Pubitemid 40365392)
57. Sawyer TK. Novel oncogenic protein kinase inhibitors for cancer therapy. Curr Med Chem Anticancer Agents 2004 ; 4 (5): 449-455 (Pubitemid 39199350)
58. Akhurst R. TGF-β antagonists: Why suppress a tumor suppressor? J Clin Invest 2002 ; 109 (12): 1533-1536
59. Benning C, Kyprianou N. Quinazoline-drive α1-adrenoreceptor antagonists Induce prostate cancer cell apoptosis via an α1- adrenoreceptor-independent action. Cancer Res 2002 ; 62 : 597-602 (Pubitemid 34106437)
60. Grimm D, Pandey K, Kay MA. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol 2005 ; 392 : 381-405 (Pubitemid 40092527)
61. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003 ; 22 : 5712-5715 (Pubitemid 37102709)
62. Piccolo S. p53 Regulation Orchestrates the TGF-α Response. Cell 2008 ; 133 : 767-768
63. Breier G, Blum S, Peli J, et al. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 2002 ; 97 (2): 142-148 (Pubitemid 34019947)
64. Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008 ; 105 : 12182-12187